The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient‐Derived Xenografts and Next‐Generation Sequencing
In conclusion, osteosarcoma with high expression of VEGFR2, PDGFRβ and CD31 is more sensitive to anlotinib. However, the potential of synergistic effect of anlotinib and chemotherapy in osteosarcoma patients needs further investigation.
Authors
- Liangbi Xiang (ORCID: https://orcid.org/0000-0002-9484-1710)
- Zuoyao Long (ORCID: https://orcid.org/0000-0002-8957-6166)
- Guojing Chen (ORCID: https://orcid.org/0009-0000-2118-7212)
- Yajie Lu (ORCID: https://orcid.org/0000-0003-4554-598X)
- Qi Wang (ORCID: https://orcid.org/0000-0002-5287-6050)
- Minghui Li (ORCID: https://orcid.org/0009-0002-5443-3197)
- Zhen Wang (ORCID: https://orcid.org/0000-0002-3640-8951)
- Fengwei Wang (ORCID: https://orcid.org/0000-0002-6886-8258)
- Jing Li (ORCID: https://orcid.org/0009-0000-6253-6423)
Institutions
- General Hospital of Shenyang Military Region (CN)
- Xijing Hospital (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/cam4.70416
- Citations
- 1
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Natural Science Foundation of Liaoning Province